10-Q: Autonomix Medical Faces Going Concern Amid Losses

Autonomix Medical, a pre-revenue medical device company, reported increased losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern despite positive clinical trial progress and patent grants.

Summary

• Autonomix Medical reported a net loss of $3.3 million for the three months ended June 30, 2025, an increase from $2.7 million in the same period of 2024.
• Cash used in operating activities increased to $2.6 million for Q2 2025, up from $1.9 million for Q2 2024.
• As of June 30, 2025, the company held $8.6 million in cash and cash equivalents and had a working capital of $7.0 million, with an accumulated deficit of $53.7 million.
• The company completed enrollment in its first-in-human proof-of-concept study (PoC 1) for pancreatic cancer pain, demonstrating statistically significant pain reductions (59.2% mean reduction among responders) and 73% of responders remaining opioid-free.
• A follow-on study (PoC 2) has been initiated, expanding the clinical focus to include earlier-stage pancreatic cancer and other visceral cancers (gallbladder, bile duct, liver), potentially doubling the addressable market.
• The company held a pre-submission meeting with the FDA in May 2025, receiving guidance for a U.S. clinical study under an Investigational Device Exemption (IDE), targeting potential De Novo approval in 2028.
• Two new U.S. patents were issued, strengthening the intellectual property portfolio related to controlled sympathectomy, micro-ablation, and neurological activity mapping.
• Subsequent to the quarter end, in July 2025, the company completed a warrant exercise inducement offer, generating approximately $2.6 million in gross proceeds.
• Also in July and August 2025, the company entered into stock option cancellation and severance agreements with certain employees, Board members, and officers, resulting in the cancellation of 234,983 stock options.
• The company's bylaws were amended on August 12, 2025, to reduce the quorum requirement for stockholder meetings from a majority to one-third of voting power.

Sentiment

Score: 3

Explanation: While there are positive clinical and regulatory developments, the severe financial situation, including increasing losses, high cash burn, explicit going concern warning, and significant capital needs with no assurance of funding, outweighs the operational progress.

Positives

• Successful completion of PoC 1 study for pancreatic cancer pain with positive preliminary results, including statistically significant pain reduction (59.2% mean reduction among responders) and 73% of responders remaining opioid-free.
• No device-related serious adverse events reported in PoC 1.
• Expansion of clinical trials with Ethics Committee approval for PoC 2, broadening the addressable market to include earlier-stage pancreatic cancer and other visceral cancers.
• Initiation of PoC 2 study with the first patient treated in June 2025.
• Positive pre-submission meeting with the FDA, providing clear guidance for a U.S. clinical study under an Investigational Device Exemption (IDE).
• Finalization of GLP preclinical study with 90-day and 180-day safety endpoints, supporting future regulatory submissions.
• Strengthening of intellectual property with the issuance of two new U.S. patents (No. 12,257,071 and No. 12,279,889 B2) related to its core technology.
• Successful capital raise of approximately $2.6 million gross proceeds from a warrant exercise inducement offer in July 2025.

Negatives

• Increased net loss to $3.3 million for Q2 2025 from $2.7 million in Q2 2024.
• Increased net cash used in operating activities to $2.6 million for Q2 2025 from $1.9 million in Q2 2024.
• The company is pre-revenue and does not expect to generate positive cash flows from operating activities in the near future.
• Current cash resources are estimated to be sufficient only into but not beyond the second calendar quarter of 2026.
• Requires substantial additional financing of $32 million to $40 million to fund operations to commercialization of its first indication.
• Substantial doubt about the company's ability to continue as a going concern within one year.
• Disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal controls (lack of segregation of duties, general technology controls, financial statement reporting).

Risks

• Inability to raise sufficient additional capital when needed or on acceptable terms.
• Failure to generate sufficient product revenues or control expenditures.
• Adverse impact on the company's ability to meet financial obligations and achieve business objectives if sufficient funds are not raised.
• Need to scale back operations if unable to raise sufficient additional funds.
• Technology remains investigational, with no guarantee of favorable clinical trial outcomes or regulatory approval.
• Challenges in scaling from current prototype (hand-assembled, 3D-printed components) to a fully integrated commercial-grade device.
• Potential product liability claims.
• Dependency on third-party manufacturers and ability to obtain all required parts.
• Ability to establish or maintain collaborations, licensing, or other arrangements.
• Ability to protect intellectual property rights.
• Risks associated with identified material weaknesses in internal control over financial reporting.
• Natural disasters affecting the company, its primary manufacturer, or suppliers.
• Ability to establish relationships with health care professionals and organizations.
• General economic uncertainty adversely affecting spending on medical procedures.
• Volatility in the market price of the stock.
• Potential dilution to current stockholders from the issuance of equity awards and future capital raising activities.
• Litigation can be costly, time-consuming, and divert management's attention.
• Uncertainty regarding the correct number of shares (271,846 shares) requested by DTCC for fractional share rounding post-reverse stock split, leading to the company's decision not to issue these shares pending inquiry.

Future Outlook

The company anticipates submitting 90-day GLP data by the end of 2025 and initiating an Early Feasibility Study (EFS) in the U.S. in the first half of 2026. It is targeting potential De Novo approval in 2028, following the EFS and a subsequent pivotal study. The company expects to incur significant expenses and operating losses for the foreseeable future as it advances its technology through development and clinical trials. It estimates current cash resources are sufficient only into but not beyond the second calendar quarter of 2026 and will require $32 million to $40 million in additional financing to reach commercialization for its first indication.

Management Comments

• We expect to incur increased research and development costs in the future as we continue with our clinical trial and product development costs.
• We estimate our current cash resources are sufficient to fund our operations into but not beyond the second calendar quarter of 2026.
• We will need to raise additional capital to meet our obligations and execute our business plan.
• We estimate that we will require additional financing of approximately $32 to $40 million to fund our operations to commercialization of our first indication.
• There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to us.
• A failure to raise sufficient capital, generate sufficient product revenues, control expenditures and regulatory matters, among other factors, will adversely impact our ability to meet our financial obligations as they become due and payable and to achieve our intended business objectives.
• If we are unable to raise sufficient additional funds, we will have to scale back our operations.

Industry Context

The company operates in the medical device sector, specifically focusing on neuromodulation and pain management, with an initial focus on pancreatic cancer pain. Its technology aims to provide minimally invasive access to deep neural structures, differentiating itself through proprietary antenna array and on-catheter signal processing for higher sensitivity and precision. The expansion into other visceral cancers aligns with a broader trend of applying advanced medical technologies to diverse oncology and gastroenterology indications. The pursuit of FDA approval (De Novo pathway) is standard for novel medical devices.

Corporate Governance

Related Party Transactions

• On July 7, 2023, the company entered into an Exclusive License Termination Agreement with a company controlled by a significant stockholder (Licensee).
• In exchange for the termination agreement, on January 29, 2024, the company issued a warrant to purchase 80,000 shares to the Licensee, valued at $8.0 million.

Stakeholder Impact

• Shareholders face potential for significant dilution from future capital raises necessary to fund operations.
• The reduction in quorum for stockholder meetings could lessen the influence of individual shareholders.
• Employees, including management, have had stock options cancelled, with severance agreements offered under certain conditions, indicating potential restructuring or cost-cutting measures.
• Creditors face increased risk due to the company's explicit 'going concern' warning and substantial ongoing losses.

Next Steps

• Submit 90-day GLP data to FDA by end of 2025.
• Initiate Early Feasibility Study (EFS) in the U.S. in the first half of 2026.
• Complete pivotal study for potential De Novo approval in 2028.
• Continue engineering refinements to ablation and sensing catheters.
• Raise additional capital of $32 million to $40 million.
• Address material weaknesses in internal control over financial reporting by hiring experienced personnel and upgrading consultants.

Key Dates

Recommendation

The company is pre-revenue with increasing net losses and cash burn, explicitly stating 'substantial doubt about its ability to continue as a going concern.' It requires a significant capital injection ($32M-$40M) to reach commercialization, with no assurance of securing these funds. While clinical progress and IP protection are positive, the severe liquidity issues and the explicit going concern warning present a high risk profile that outweighs the operational advancements. The recent capital raise is insufficient to address the long-term funding gap, indicating a high probability of further dilution or financial distress.

Keywords

Medical device, Neuromodulation, Pancreatic cancer, Pain management, RF ablation, Clinical trials, FDA approval, Life sciences, Autonomix Medical, AMIX, Corporate governance, Capital raise